Alzheimer's Drug Discovery Foundation Raises $1.1M for New Clinical Trial in Alzheimer's - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Alzheimer's Drug Discovery Foundation Raises $1.1M for New Clinical Trial in Alzheimer's Drug Could Be the First to Slow the Progression of Alzheimer's Disease


Alzheimer's Drug Discovery Foundation Raises $1.1M for New Clinical Trial in Alzheimer's

Drug Could Be the First to Slow the Progression of Alzheimer's Disease

PR Newswire

NEW YORK, May 2, 2014 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it raised more than $1.1 million in support of a clinical trial to test an existing drug for the treatment of Alzheimer's disease.  The $1.1 million was generated during the "Fund a Scientist" auction at its Eighth Annual Connoisseur's Dinner on May 1, 2014, and awarded to Jeffrey Cummings, MD, director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio. Dr. Cummings will investigate rasagiline, an FDA-approved treatment for Parkinson's disease with the potential to be the first drug to slow the course of Alzheimer's disease.

Alzheimer's Drug Discovery Foundation

"Repurposing is an exciting approach because we can study drugs that are already approved by the FDA for use by physicians to treat other diseases. The results of this study may provide physicians on the frontlines of Alzheimer's treatment with new and critical evidence to inform the treatment and care of their patients," said Howard Fillit, MD, executive director and chief science officer, ADDF.

Previous research has shown that rasagiline could be a viable therapeutic option for people with Alzheimer's disease. It has already proven safe and effective in Parkinson's disease, a neurodegenerative illness similar to Alzheimer's disease in many ways.

"Rasagiline has neuroprotective properties, offering a novel approach to Alzheimer's drug therapy," says Dr. Fillit. "Currently, most Alzheimer's drug research targets beta-amyloid, a protein found in the brain of individuals with Alzheimer's."

Results of Dr. Cummings' study, which was designed in collaboration with the ADDF's team of neuroscientists, may be available in as little as two years.

In total, the Eighth Annual Connoisseur's Dinner raised over $3.5 million to accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease.

About the Alzheimer's Drug Discovery Foundation (ADDF)
The mission of the Alzheimer's Drug Discovery Foundation (ADDF) is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer's diseases, related dementias and cognitive aging. The ADDF has granted more than $65 million to fund nearly 450 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries. In 2013, 100 percent of funds raised by the ADDF went directly to Alzheimer's drug research and other related programs.  For more information, please visit www.AlzDiscovery.org.

Logo - http://photos.prnewswire.com/prnh/20130909/DC75486LOGO

SOURCE Alzheimer's Drug Discovery Foundation

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here